A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Table 1

The clinical characteristics of the patients.

	Total ()	High PMI ()	Low PMI ()	value
Age (years)
<65	13 (48.1%)	7 (53.8%)	6 (42.9%)	0.568
≥65	14 (51.9%)	6 (46.2%)	8 (57.1%)
Gender
Female	6 (22.2%)	3 (23.1%)	3 (21.4%)	0.918
Male	21 (77.8%)	10 (76.9%)	11 (78.6%)
Creatinine clearance (mL/min.)
<60	12 (44.4%)	6 (46.2%)	6 (42.9%)	0.8632
≥60	15 (55.6%)	7 (53.8%)	8 (57.1%)
Cystectomy or nephroureterectomy
Yes	16 (59.3%)	10 (76.9%)	6 (42.9%)	0.0719
No	11 (40.7%)	3 (23.1%)	8 (57.1%)
Response after 2 courses of GN therapy
CR and PR	13 (48.1%)	10 (76.9%)	3 (21.4%)	0.0719
SD and PD	14 (51.9%)	6 (46.2%)	8 (57.1%)
Adverse effects (grade ≥ 3)
Neutropenia	25 (92.6%)	12 (92.3%)	13 (92.9%)	0.9566
Thrombocytopenia	17 (63.0%)	8 (61.5%)	9 (64.3%)	0.6802
Appetite loss or nausea	1 (3.7%)	1 (7.7%)	0 (0%)	0.2903